TCI Gene (6879.TWO) Stock Price

TCI GENE, Inc. generates revenue through genetic testing services, virus testing services, and cell experiment services. The company produces adipose-derived stem cell preparations for degenerative arthritis and knee cartilage defects, as well as natural killer cell preparations for solid cancer treatment. Personalized genetic health food is also a key product. These offerings are primarily sold within Taiwan, targeting consumers interested in disease risk assessment, drug genetic testing, and personalized health solutions. The firm's comprehensive genetic testing covers areas like child growth, youth beauty, weight management, and cardiovascular drug responses, while pharmacogenetic testing addresses depression and insomnia. The company's product portfolio includes specialized services such as youth beauty genetic testing and anti-aging genetic testing, which appeal to wellness-focused segments. Adipose-derived stem cell preparations are marketed for orthopedic applications, and natural killer cell preparations target cancer patients seeking alternative therapies. Personalized genetic health food is positioned for consumers seeking tailored nutritional support based on genetic profiles. All products are distributed exclusively in Taiwan, with no international market presence mentioned. TCI GENE, Inc. serves customers seeking preventive health management through genetic insights. The primary buyers are individuals in Taiwan interested in disease risk prediction, drug response optimization, and personalized wellness. The firm's focus on genetic health food and cell-based treatments targets health-conscious consumers and patients requiring specialized medical solutions. Sales are concentrated within Taiwan, reflecting the company's localized market strategy.